Anzeige
Mehr »
Login
Mittwoch, 15.01.2025 Börsentäglich über 12.000 News von 681 internationalen Medien
Löst diese riesige Entdeckung die Kupferkrise der KI? So ändert sich die Rechnung durch diesen Explorer!!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3DAGC | ISIN: US86882L2043 | Ticker-Symbol: 9B90
Tradegate
13.01.25
19:01 Uhr
1,536 Euro
-0,022
-1,41 %
1-Jahres-Chart
SURGEPAYS INC Chart 1 Jahr
5-Tage-Chart
SURGEPAYS INC 5-Tage-Chart
RealtimeGeldBriefZeit
1,6201,69816:58
1,6301,69016:54
ACCESSWIRE
74 Leser
Artikel bewerten:
(0)

GPO Plus, Inc.: GPOPlus+ Teams Up With SurgePays to Launch New Sales Channels

Finanznachrichten News

SurgePays will initiate a dedicated outbound sales team to sell GPOX products from its 100+ person operations center in El Salvador.

LAS VEGAS, NV AND BARTLETT, TN / ACCESSWIRE / January 15, 2025 / GPO Plus, Inc. (OTCQB:GPOX), an AI-powered Distributor revolutionizing distribution to gas stations and convenience stores with its innovative technology-driven Direct Store Delivery (DSD) model, and SurgePays, Inc. (NASDAQ:SURG), a technology and telecommunications company, are pleased to announce a strategic partnership to develop new sales channels.

SurgePays will build and direct a dedicated outbound sales team for GPOX from its new operations center in El Salvador. The outbound sales initiative will focus on driving outreach to independent retailers, including convenience stores, bodegas, liquor stores, and smoke shops-key markets for GPOX's high-demand product lines.

Strategic Benefits of the Partnership:

  • Expanded Sales Outreach: Leverages SurgePays' expertise in outbound sales and financial technology with GPOX's high-demand product sourcing and distribution network to deliver impactful solutions for independent retailers.

  • Access to a Broad Network: Utilizes SurgePays' existing retail relationships and vast store database to accelerate customer acquisition and expand the retail network for both companies.

  • Operational Efficiency: Streamlines sales processes and enhances outreach by focusing on each company's core competencies-SurgePays in sales and financial technology, GPOX in sourcing and distribution.

SurgePays brings a proven sales and marketing infrastructure, a pioneering operational team, a sales operations center of 100 bilingual team members, patent-pending POS marketing software, and an existing nationwide retail network of thousands of stores. This collaboration provides GPOX with a scalable, cost-efficient solution to penetrate deeper into existing markets and capture new retail partners. The relationship aligns perfectly, combining SurgePays' expertise in outbound sales and POS software with GPOX's focus on high-demand product distribution. This initiative should strengthen existing retail networks while expanding the market presence of both companies.

"We are excited about our partnership with SurgePays, as it marks a significant step forward in enhancing our sales capabilities," said Brett H. Pojunis, CEO of GPOX. "SurgePays' infrastructure and extensive retail network align perfectly with our strategy to scale operations. This collaboration will allow us to target new retail partners, drive revenue growth, and expand our distribution footprint across key independent retail markets."

Brian Cox, CEO of SurgePays, added, "We see a lot of synergy with GPOX, and I am a fan of the DSD model. I'm excited to see how fast we can scale our operations center's capabilities to launch targeted outbound sales campaigns. The goal is to upsell to our nationwide network of stores while attracting new retailers through compelling product offers fulfilled directly by GPOX."

This collaboration highlights GPOX's and SurgePays's dedication to innovation, operational excellence, and sustainable growth. By utilizing SurgePays' proven capabilities, GPOX is well-positioned to expand its market reach, enhance its sales channels, and strengthen its position as a leading distributor to independent retailers nationwide.

To learn more, visit GPOPlus.com.

Connect with us on social media to view live video updates, content, and general information about GPOX: https://gpoplus.com/social.

About GPOPlus+ (GPOX)
GPOX is an AI-powered Distributor revolutionizing the future of distribution to gas stations and convenience stores with its innovative technology-driven Direct Store Delivery (DSD) model. Our goal is clear and ambitious: "to build the largest nationwide DSD distribution company servicing gas stations, convenience stores, and beyond." Our technology-driven AI network, featuring strategically placed Regional Hubs and Mini Hubs, is designed to optimize efficiency and maximize reach. Central to our operations is our in-house AI technology platform, PRISM+. Designed to streamline the distribution process, PRISM+ supports efficient delivery, inventory management, data analytics, and overall operational excellence, enabling us to reliably and effectively meet the dynamic needs of our partners. Our mission is to consolidate the fragmented market segment managed by numerous regional vendors. Our dedication to excellence is evident in our product selection process, where we align offerings with consumer demand and partner with top-tier vendors and brands, ensuring our portfolio remains diverse and highly profitable.

For more information, please visit www.GPOPlus.com.

About SurgePays, Inc. (SURG)
SurgePays, Inc. provides prepaid wireless and point-of-sale platform services in underserved communities utilizing convenience stores, bodegas, and other neighborhood stores.

Please visit SurgePays.com for more information.

Information about Forward-Looking Statements

This press release contains "forward-looking statements" that include statements regarding expected financial performance and growth information relating to future events. Forward-looking statements include statements with respect to beliefs, plans, objectives, goals, expectations, anticipations, assumptions, estimates, intentions, and future performance, and involve known and unknown risks, uncertainties and other factors, which may be beyond the control of the Company and its officers and managers, and which may cause actual results, performance or achievements to be materially different from future results, performance or achievements expressed or implied by such forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and will not necessarily be accurate indications of the times at, or by which, that performance or those results will be achieved. Forward-looking statements are based on information available at the time they are made and/or management's good faith belief as of that time with respect to future events and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in, or suggested by, the forward-looking statements. Important factors that could cause these differences include, but are not limited to; inability to gain or maintain licenses, reliance on unaudited statements, the Company's need for additional funding, governmental regulation of the cannabis industry, the impact of competitive products and pricing, the demand for the Company's products, and other risks that are detailed from time-to-time in the Company's filings with the United States Securities and Exchange Commission. All statements other than statements of historical fact are statements that could be forward-looking statements. You can typically identify these forward-looking statements through use of words such as "may," "will," "can" "anticipate," "assume," "should," "indicate," "would," "believe," "contemplate," "expect," "seek," "estimate," "continue," "plan," "point to," "project," "predict," "could," "intend," "target," "potential," and other similar words and expressions of the future. The Company expresses its expectations, beliefs and projections in good faith and believes that its expectations reflected in these forward-looking statements are based on reasonable assumptions. However, there is no assurance that these expectations, beliefs and projections will prove to have been correct. Such statements reflect the current views of the Company with respect to its operations and future events, and are subject to certain risks, uncertainties and assumptions relating to its proposed operations, including the risk factors set forth herein. Should one or more of these risks or uncertainties materialize or should the underlying assumptions prove incorrect, the Company's actual results may vary significantly from those intended, anticipated, believed, estimated, expected or planned. In light of these risks, uncertainties and assumptions, any favorable forward-looking events discussed herein might not be realized and occur. The Company has no obligation to update or revise its forward-looking statements, whether as a result of new information, future events or otherwise. For a more detailed description of the risk factors and uncertainties affecting GPO Plus, Inc. GPOX, please refer to the Company's recent Securities and Exchange Commission filings, which are available at www.sec.gov. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise.

Company Contacts:

GPOX Shareholder Success Team:
Brett H. Pojunis, CEO
Email: ir@gpoplus.com
Shareholder's Line: 855.935.GPOX (4769)

SurgePay Team:
3124 Brother Blvd, Suite 104
Bartlett, TN 38133

SOURCE: GPO Plus, Inc.



View the original press release on accesswire.com

© 2025 ACCESSWIRE
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.